Investing.com - Financial Markets Worldwide

BRIEF-Novavax Says Interim Data In Covid-19 Phase 3 Trial In Uk Expected As Soon As Early Q1 2021

Published 30/11/2020, 11:58 pm

Nov 30 (Reuters) - Novavax:

* NOVAVAX SAYS U.S./MEXICO COVID-19 PHASE 3 TRIAL EXPECTED TO BEGIN IN THE COMING WEEKS

* NOVAVAX - HAS BEEN WORKING CLOSELY WITH FDA TO COMPLETE TRIAL-INITIATION GATING ACTIVITIES RELATED TO COMMERCIAL-SCALE PRODUCTION IN NORTH CAROLINA

* NOVAVAX - WILL USE VACCINE MATERIAL PRODUCED AT COMMERCIAL SCALE FOR U.S./MEXICO COVID-19 PHASE 3 TRIAL

* NOVAVAX SAYS PIVOTAL COVID-19 PHASE 3 TRIAL IN UK & PHASE2B EFFICACY TRIAL IN SOUTH AFRICA COMPLETES ENROLLMENT

* NOVAVAX - INTERIM DATA IN COVID-19 PHASE 3 TRIAL IN UK EXPECTED AS SOON AS EARLY Q1 2021, ALTHOUGH TIMING DEPENDS ON COVID-19 RATE IN THE REGION

* NOVAVAX, ON COVID-19 PHASE 2B TRIAL IN SOUTH AFRICA, SAYS AVAILABILITY OF EFFICACY DATA DEPENDS ON ILLNESS RATE & MAY BE AVAILABLE AS SOON AS Q1 2021

* NOVAVAX - MORE THAN 25% OF ENROLLEES IN COVID-19 PHASE 3 TRIAL IN UK ARE OVER THE AGE OF 65

* NOVAVAX - ADDITIONAL CLINICAL DATA FROM COVID-19 PHASE 2 TRIAL IN U.S., AUSTRALIA EXPECTED TO BE UNBLINDED IN Q1, WILL BE TARGETED FOR PUBLICATION

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.